Cellectis
Paris, FR· latest recorded location
CELLECTIS is named on 119 US grants and 225 published applications in this corpus. Its most frequent classification is C12N (Microorganisms or enzymes).
- Granted patents
- 119
- Published applications
- 225
- Inventors
- 129
- Granted in 2026 so far
- 6
- Most recent grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 1 | 11 |
| 2011 | 2 | 13 |
| 2012 | 4 | 14 |
| 2013 | 3 | 18 |
| 2014 | 5 | 15 |
| 2015 | 3 | 12 |
| 2016 | 4 | 22 |
| 2017 | 1 | 16 |
| 2018 | 9 | 16 |
| 2019 | 18 | 16 |
| 2020 | 16 | 17 |
| 2021 | 10 | 13 |
| 2022 | 10 | 5 |
| 2023 | 12 | 9 |
| 2024 | 9 | 9 |
| 2025 | 5 | 7 |
| 2026 | 6 | 4 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 344 documents
- C12NMicroorganisms or enzymes323
- A61KMedicines and medical preparations222
- A61PTherapeutic uses of medicines221
- C07KPeptides215
- C12YEnzymes52
- A01KAnimal husbandry31
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition24
- A01HNew plants or non-transgenic processes for obtaining them14
- Y02ATechnologies for adaptation to climate change14
- G01NInvestigating or analysing materials by determining their chemical or physical properties12
Recent patents
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2
- Methods for engineering allogeneic and highly active T cell for immunotheraphy14 Jul 2026US 12,680,076 B2
- TAL-effector nuclease (TALEN)-modified allogenic cells suitable for therapy16 Jun 2026US 12,655,451 B2
- Dual CAR-T cells5 May 2026US 12,618,048 B2
- Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells17 Mar 2026US 12,577,581 B2
- Processes for generating til products using pd-1/tigit talen double knockdown13 Aug 2026US 2026/0234556 A1
- Electroporation device and method23 Jul 2026US 2026/0209675 A1
- Dual car-t cells23 Jul 2026US 2026/0209703 A1
- Processes for generating til products using pd-1/tigit talen double knockdown5 Mar 2026US 2026/0061052 A1
- Method for improving production of car t cells27 Nov 2025US 2025/0361301 A1
Most cited
By later US patents
- Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof45US 7,842,489 B22010
- Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system42US 9,855,297 B22018
- Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations40US 8,802,437 B22014
- Anti-bacterial composition especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent31US 8,293,700 B22012
- Random integration of a polynucleotide by in vivo linearization29US 7,098,031 B22006